Item 5.02 Departure of Directors or Certain Officers; Election of Directors;


          Appointment of Certain Officers; Compensatory Arrangements of Certain
          Officers.

Amendment to the Akers Bioscience, Inc. 2018 Equity Incentive Plan

On August 27, 2020, Akers Biosciences, Inc. (the "Company") held its 2020 annual meeting of stockholders (the "Annual Meeting"), which was held virtually. At the Annual Meeting, the stockholders approved an amendment (the "2018 Plan Amendment") to the Akers Biosciences, Inc. 2018 Equity Incentive Plan ("2018 Plan") to increase the number of shares of common stock available for issuance pursuant to awards under the 2018 Plan by an additional 1,042,000 shares, to a total of 1,120,125 shares of the Company's common stock.





Election of Four Directors

As previously reported in the Company's definitive proxy statement filed with the Securities and Exchange Commission on July 29, 2020 (the "2020 Proxy"), the terms of the Company's four directors were scheduled to expire at the Annual Meeting, and each of the four directors were nominated for re-election at the Annual Meeting.

At the Annual Meeting, Christopher C. Schreiber, Joshua Silverman, Bill J. White and Robert C. Schroeder were elected as directors of the Company's board of directors to serve for a term expiring at the Company's 2021 annual meeting of stockholders.

For more information about the matters above, see the Company's 2020 Proxy, the relevant portions of which are incorporated herein by reference. The description of the 2018 Plan Amendment above and such portions of the 2020 Proxy are qualified in their entirety by reference to the full text of the 2018 Plan Amendment, filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.

Item 5.07 Submission of Matters to a Vote of Security Holders.

At the Company's Annual Meeting, a total of 26,109,110 shares of the Company's common stock were present in person or represented by proxy with each holder of the Company's common stock entitled to one vote per share, and certain holders of the Company's Series D Convertible Preferred Stock, subject to certain restrictions and the beneficial ownership limitation pursuant to the terms of such preferred stock as set forth in the certificate of designation for such preferred stock, were present in person or represented by proxy and entitled to an aggregate of 36,973 votes. The number of votes cast for and against and the number of abstentions and broker non-votes with respect to each matter voted upon are set forth below:





  1) Approval, pursuant to Nasdaq listing rule 5635(a), of the issuance of shares
     of our common stock upon conversion of Series D Preferred Stock in excess of
     20% of our common stock outstanding.

Votes Cast For Votes Cast Against Abstentions Broker Non-Votes


   469,032             85,076            8,668         3,063,001












  2) Approval, pursuant to Nasdaq listing rule 5635(a), of the potential issuance
     of our common stock in excess of 20% of our common stock outstanding in
     connection with milestone shares that may become issuable in the future.

Votes Cast For Votes Cast Against Abstentions Broker Non-Votes


   473,279             81,571            7,926         3,063,001




  3) To elect four (4) directors to serve until our 2021 Annual Meeting of
     Stockholders or until their successors are elected and qualified or until
     their earlier incapacity, removal or resignation.




                             For     Against   Withheld   Broker Non-Votes
Christopher C. Schreiber   536,982     N/A      25,794       3,063,001
Joshua Silverman           528,738     N/A      34,038       3,063,001
Bill J. White              526,749     N/A      36,027       3,063,001
Robert C. Schroeder        536,016     N/A      26,760       3,063,001




  4) Approval of the 2018 Plan Amendment to the 2018 Plan to increase the total
     number of shares of Common Stock authorized for issuance under such plan by
     1,042,000, to a total of 1,120,125 shares.




  For     Against   Abstentions   Broker Non-Votes
441,294   82,174      39,308         3,063,001




  5) To ratify the appointment of Morison Cogen LLP as the Company's independent
     registered public accounting firm for the fiscal year ending December 31,
     2020.

Votes Cast For Votes Cast Against Abstentions Broker Non-Votes


  3,491,958            27,930           105,889            0




  6) Approval, on an advisory basis, of the compensation paid to our named
     executive officers.




Votes Cast For   Votes Cast Against   Abstentions   Broker Non-Votes
   429,753            116,734           16,289         3,063,001

7) Approval, on an advisory basis, of the frequency of future advisory votes on


     the compensation paid to our named executive officers.




1 Year    2 Years   3 Years   Abstentions   Broker Non-Votes
154,975   19,455    337,366     50,980         3,063,001

Item 9.01 Financial Statements and Exhibits.






(d) Exhibits.



Exhibit No.                     Description

10.1            Akers Biosciences, Inc. 2018 Plan Amendment

© Edgar Online, source Glimpses